<?xml version='1.0' encoding='utf-8'?>
<document id="31953695"><sentence text="A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer."><entity charOffset="110-120" id="DDI-PubMed.31953695.s1.e0" text="paclitaxel" /><entity charOffset="125-136" id="DDI-PubMed.31953695.s1.e1" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.31953695.s1.e0" e2="DDI-PubMed.31953695.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31953695.s1.e0" e2="DDI-PubMed.31953695.s1.e1" /></sentence><sentence text="Upregulation of Notch pathway is associated with poor prognosis in breast cancer" /><sentence text=" We present the results of a phase I study of an oral selective gamma secretase (GS) inhibitor (critical to Notch signaling), RO4929097 in combination with neoadjuvant chemotherapy for operable triple negative breast cancer" /><sentence text=" The primary objective was to determine the maximum tolerated dose (MTD) of RO4929097" /><sentence text=" Secondary objectives were to determine real-time pharmacokinetics of RO4929097 and paclitaxel, safety and pathologic (pCR) complete response to study treatment"><entity charOffset="70-79" id="DDI-PubMed.31953695.s5.e0" text="RO4929097" /><entity charOffset="84-94" id="DDI-PubMed.31953695.s5.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.31953695.s5.e0" e2="DDI-PubMed.31953695.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31953695.s5.e0" e2="DDI-PubMed.31953695.s5.e1" /></sentence><sentence text=" Eligible patients, initiated carboplatin at AUC 6 administered intravenously (IV) on day 1, weekly paclitaxel at 80 mg/m2 IV and RO4929097 10 mg daily given orally (PO) on days 1-3, 8-10 and 15-17 for six 21-day cycles"><entity charOffset="30-41" id="DDI-PubMed.31953695.s6.e0" text="carboplatin" /><entity charOffset="100-110" id="DDI-PubMed.31953695.s6.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.31953695.s6.e0" e2="DDI-PubMed.31953695.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31953695.s6.e0" e2="DDI-PubMed.31953695.s6.e1" /></sentence><sentence text=" RO4929097 was escalated in 10 mg increments using the 3 + 3 dose escalation design" /><sentence text=" Two DLTs were observed in 14 patients - Grade (G) 4 thrombocytopenia in dose level 1 (10 mg) and G3 hypertension in dose level 2 (20 mg)" /><sentence text=" Protocol-defined MTD was not determined due to discontinuation of RO4929097 development" /><sentence text=" However, 4 of 5 patients enrolled to 20 mg dose of RO4929097 required dose reduction to 10 mg due to toxicities (including neutropenia, thrombocytopenia and hypertension) occurring during and beyond the DLT observation period" /><sentence text=" Thus, 10 mg would have been the likely dose level for further development" /><sentence text=" G3 or higher hematologic toxicities included neutropenia (N = 8, 57%) and thrombocytopenia (N = 5, 36%) patients" /><sentence text=" Six (43%) patients had G2-3 neuropathy requiring paclitaxel dose reduction"><entity charOffset="50-60" id="DDI-PubMed.31953695.s13.e0" text="paclitaxel" /></sentence><sentence text=" No signs of drug-drug interaction between paclitaxel and RO4929097 were evident"><entity charOffset="43-53" id="DDI-PubMed.31953695.s14.e0" text="paclitaxel" /><entity charOffset="58-67" id="DDI-PubMed.31953695.s14.e1" text="RO4929097" /><pair ddi="false" e1="DDI-PubMed.31953695.s14.e0" e2="DDI-PubMed.31953695.s14.e0" /><pair ddi="false" e1="DDI-PubMed.31953695.s14.e0" e2="DDI-PubMed.31953695.s14.e1" /></sentence><sentence text=" Five patients (36%) had pCR" /><sentence text="" /></document>